Edition:
United States

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

453JPY
20 Oct 2017
Change (% chg)

¥22 (+5.10%)
Prev Close
¥431
Open
¥432
Day's High
¥465
Day's Low
¥429
Volume
7,099,000
Avg. Vol
8,590,056
52-wk High
¥938
52-wk Low
¥142

Latest Key Developments (Source: Significant Developments)

GNI Group gets IND clearance by FDA for liver fibrosis treatment
Monday, 9 Oct 2017 04:00pm EDT 

Oct 9 (Reuters) - GNI Group Ltd <2160.T>:GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis.‍GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017​.‍GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018​.Preliminary results are expected within 2018​.  Full Article

GNI Group says exercise of options
Tuesday, 18 Jul 2017 05:03am EDT 

July 18 (Reuters) - GNI Group Ltd <2160.T>:* Says 4,082 units of its 40th series options were exercised to 4.1 million shares of its common stock, from July 3 to July 18 .  Full Article

GNI Group unit GNI USA to sell stake in IriSys for $3.8 mln and GNI Group to acquire stake in GNI-EPS (HONG KONG) HOLDINGS for $4.2 mln
Friday, 30 Jun 2017 02:24am EDT 

June 30(Reuters) - GNI Group Ltd <2160.T>:Says its wholly owned unit GNI USA, Inc will sell 242,029 voting rights in IriSys, LLC to EPS Americas, Corp., for $3.8 million (425.2 million yen), on July 31, and will cut voting power in IriSys, LLC to 15 percent from 35 percent.Says it will acquire 3.3 million shares of GNI-EPS (HONG KONG) HOLDINGS LIMITED for $4.2 million (470.4 million yen) on July 31, and will increase voting power in GNI-EPS (HONG KONG) HOLDINGS LIMITED to 53.6 percent from 43.1 percent .  Full Article

GNI Group says exercise of options
Tuesday, 20 Jun 2017 03:36am EDT 

June 20 (Reuters) - GNI Group Ltd <2160.T>:* Says 2,102 units of its 40th series options were exercised to 2,102,000 shares of its common stock from June 15 to June 20.  Full Article

GNI Group says exercise of options
Wednesday, 14 Jun 2017 04:07am EDT 

June 14 (Reuters) - GNI Group Ltd <2160.T>:* Says 5,909 units of its 40th series options were exercised to 5.9 million shares of its common stock, from June 13 to June 14.* Says the shares were exercised at the price of 368 yen per share on June 13, and 372 yen per share on June 14.  Full Article

GNI Group announces exercise of options
Monday, 12 Jun 2017 03:27am EDT 

June 12(Reuters) - GNI Group Ltd <2160.T>:Says 2,196 units of its 40th series options were exercised to 2.2 million shares of its common stock from June 5 to June 12.  Full Article

GNI Group announces exercise of options
Friday, 2 Jun 2017 03:37am EDT 

June 2(Reuters) - GNI Group Ltd <2160.T>:Says 2,055 units of its 40th series options were exercised to 2.1 million shares of its common stock on June 1 and June 2.Says the shares were exercised at the price of 378 yen per share on June 1 and 379 yen per share on June 2.  Full Article

OFFICIAL-BRIEF-GNI Group to acquire Berkeley Advanced Biomaterials through GNI USA(April 18)
Wednesday, 19 Apr 2017 05:22am EDT 

Corrects target company name in headline and text after GNI Group officially corrects statement:* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterials, Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc..* Says Berkeley Advanced Biomaterials,Inc. will set up a new unit, and transfer all property and business to unit .* Says transaction effective July 31.  Full Article

GNI Group to acquire Berkeley Advanced Biomaterial through GNI USA
Tuesday, 18 Apr 2017 04:41am EDT 

April 18 (Reuters) - GNI Group Ltd <2160.T>:* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterial,Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc..* Says Berkeley Advanced Biomaterial,Inc. will set up a new unit, and transfer all property and business to unit .* Says transaction effective July 31.  Full Article

GNI Group gets approval for clinical trial in China for drug of diabetic nephropathy
Wednesday, 17 Aug 2016 04:16am EDT 

GNI Group Ltd <2160.T>:Says it received approval from China Food and Drug Administration for a pulmonary fibrosis treatment drug's effect on diabetic nephropathy.  Full Article

BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment

* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis